By contrast, while showing a marked trend in favor of icatibant in the US (FAST-1) trial, the difference between icatibant and placebo did not reach significance for several endpoints, including the primary end point. 40 This is likely to result from underpowering, since the low numbers were randomized for a treatment where delayed and variable responses are expected, and where the outcome measures are subjective.
← all excerpts
Management of acute attacks of hereditary angioedema: potential role of icatibant.
1
—
—